FDA NEWS

Bio-Path Holdings, Inc. Announces Additional Key Personnel Joining Its - Forbes
Bio-Path Holdings, Inc., a publicly traded biotechnology company with drug development operations in Houston, Texas (Pink Sheets: BPTH), announced today that Dai-Shan Wong, B.S., RAC and Thomas A. Walker, Ph.D. have joined the Company's drug
Source: www.forbes.com

Amgen says US FDA decision on clot drug delayed - Reuters
WASHINGTON, July 23 (Reuters) - The Food and Drug Administration will not rule on Amgen Inc's (AMGN.O: Quote , Profile , Research , Stock Buzz ) experimental clotting disorder drug Nplate by Wednesday's action date, an Amgen spokeswoman said on
Source: www.reuters.com

Genzyme shares fall on more Myozyme delays - CNBC
NEW YORK - Shares of Genzyme Corp. fell Wednesday after the company reported positive second-quarter financial results but said plans to increase production of its genetic disorder drug Myozyme could be further delayed, pending a regulatory review
Source: www.cnbc.com

New drug prolongs survival of advanced kidney cancer - Reuters UK
NEW YORK (Reuters Health) - Treatment with everolimus can significantly improve the progression-free survival of patients with advanced kidney cancer that has not responded to other treatments, according to a report in the online issue of The Lancet
Source: uk.reuters.com

Mexico hot under the collar at U.S. pepper scare - San Diego Union-Tribune
MEXICO CITY – Mexicans are jumping to the defense of the jalapeno pepper, maligned by U.S. health inspectors in a salmonella scare but loved by millions in its ancient home and growing in popularity north of the border. The U.S. Food and Drug
Source: www.signonsandiego.com

US Cong seeks details of Ranbaxy drug approvals - Business Standard
Two United States senators have asked the US Food and Drug Administration (USFDA) to provide details of market approvals given to all medicines sold by India's largest drug-maker Ranbaxy in that country. The senators, John Dingell and Bart Stupak
Source: www.business-standard.com